Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Intellia Therapeutics Insiders Buying or Selling?
Intellia Therapeutics (NTLA) has had 4 insider transactions in the past 90 days, all sells. The most recent was Michael Dube, who sold 1,864 shares at $12.43 on October 2, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the NTLA AI Score. For government officials trading this stock, see NTLA congressional trading.
Who’s Trading Intellia Therapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| JOHN LEONARD | Sold $1.8M | 7 | Aug 21, 2026 |
| Fred Cohen | Bought $1.4M | 1 | Jan 5, 2026 |
| WILLIAM CHASE | Bought $1M | 1 | Aug 20, 2025 |
| Dulac Edward J III | Sold $340,000 | 4 | Jul 22, 2026 |
| David Lebwohl | Sold $230,000 | 2 | Jan 5, 2026 |
| JAMES BASTA | Sold $220,000 | 4 | Mar 2, 2026 |
Recent Intellia Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Michael Dube | Oct 2, 2026 | Sell | 1,864 | $12.43 | $23,000 |
| JOHN LEONARD | Aug 21, 2026 | Sell | 2,785 | $13 | $36,000 |
| JOHN LEONARD | Aug 20, 2026 | Sell | 19,890 | $12.6 | $250,000 |
| Dulac Edward J III | Jul 22, 2026 | Sell | 8,111 | $11.25 | $91,000 |
| Dulac Edward J III | Jul 2, 2026 | Sell | 4,677 | $18 | $84,000 |
| Michael Dube | Jul 1, 2026 | Sell | 2,641 | $16.78 | $44,000 |
| JAMES BASTA | Mar 2, 2026 | Sell | 1,211 | $13.78 | $17,000 |
| Eliana Clark | Mar 2, 2026 | Sell | 607 | $13.78 | $8,400 |
| Fred Cohen | Jan 5, 2026 | Buy | 150,000 | $9.35 | $1.4M |
| JOHN LEONARD | Jan 5, 2026 | Sell | 34,146 | $9.21 | $310,000 |
| JAMES BASTA | Jan 5, 2026 | Sell | 10,397 | $9.21 | $96,000 |
| David Lebwohl | Jan 5, 2026 | Sell | 11,903 | $9.21 | $110,000 |
| Birgit Schultes | Jan 5, 2026 | Sell | 8,508 | $9.21 | $78,000 |
| Eliana Clark | Jan 5, 2026 | Sell | 9,515 | $9.21 | $88,000 |
| Dulac Edward J III | Jan 5, 2026 | Sell | 6,379 | $9.21 | $59,000 |
| Michael Dube | Jan 5, 2026 | Sell | 2,989 | $9.21 | $28,000 |
| JOHN LEONARD | Dec 11, 2025 | Sell | 49,959 | $9.49 | $470,000 |
| JOHN LEONARD | Dec 11, 2025 | Sell | 32,832 | $9.47 | $310,000 |
| JOHN LEONARD | Dec 11, 2025 | Sell | 5,355 | $9.59 | $51,000 |
| Michael Dube | Oct 1, 2025 | Sell | 1,871 | $17.38 | $33,000 |
| Birgit Schultes | Oct 1, 2025 | Sell | 31 | $17.38 | $540 |
| WILLIAM CHASE | Aug 20, 2025 | Buy | 100,000 | $10.03 | $1M |
| Dulac Edward J III | Jul 23, 2025 | Sell | 7,462 | $14.02 | $100,000 |
| Michael Dube | Jul 2, 2025 | Sell | 2,503 | $9.95 | $25,000 |
| Eliana Clark | Jul 1, 2025 | Sell | 1,022 | $9.82 | $10,000 |
| JESSE GOODMAN | Jul 1, 2025 | Sell | 1,547 | $9.23 | $14,000 |
| Muna Bhanji | Apr 29, 2025 | Sell | 265 | $8.5 | $2,300 |
| JAMES BASTA | Mar 4, 2025 | Sell | 2,572 | $8.99 | $23,000 |
| Eliana Clark | Mar 4, 2025 | Sell | 679 | $8.99 | $6,100 |
| Muna Bhanji | Jan 29, 2025 | Sell | 265 | $9.97 | $2,600 |
| JOHN LEONARD | Jan 3, 2025 | Sell | 26,807 | $12.18 | $330,000 |
| Michael Dube | Jan 3, 2025 | Sell | 1,372 | $12.18 | $17,000 |
| JAMES BASTA | Jan 3, 2025 | Sell | 7,074 | $12.18 | $86,000 |
| David Lebwohl | Jan 3, 2025 | Sell | 9,557 | $12.18 | $120,000 |
| Derek Hicks | Jan 3, 2025 | Sell | 6,502 | $12.18 | $79,000 |
| Laura Sepp-Lorenzino | Jan 3, 2025 | Sell | 8,966 | $12.18 | $110,000 |
| Eliana Clark | Jan 3, 2025 | Sell | 7,422 | $12.18 | $90,000 |
| Eliana Clark | Jan 2, 2025 | Sell | 556 | $12.03 | $6,700 |
Frequently Asked Questions: Intellia Therapeutics Insider Trading
In the past 90 days, Intellia Therapeutics insiders have made 0 buys and 4 sells. The net selling may indicate insiders are taking profits or reducing exposure.
The most recent sale was by Michael Dube who sold 1,864 shares on October 2, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Cohen Fred E has bought the most NTLA stock in the last 2 years, with a total value of $1.4M.
LEONARD JOHN M has sold the most NTLA stock in the last 2 years, with a total value of $1.8M.
The total value of insider transactions for Intellia Therapeutics in the last 2 years is negative, amounting to -$810,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
